Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

Posová, Helena; Horáková, Dana; Čapek, Václav; Uher, Tomáš; Hrušková, Zdenka; Havrdová, Eva

doi:10.1186/s12883-017-0915-1

BMC Neurology

Table 1 a, b Median ± standard deviation of lymphocyte subpopulations (in % of all lymphocytes) in different subgroups

From: Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

a
	n	T ly	CD4+	CD8+	B ly	NK cells	CD5+
all patients at first relapse	191	71.8 ± 7	44.6 ± 7	23 ± 6	11.1 ± 4	14 ± 7	72 ± 7
all patients at baseline (BL)^a	191	71.5 ± 7	43 ± 8	24 ± 7	9.3 ± 4	16.1 ± 7	71 ± 9
all patients at 48 months (48)^b	181	72.5 ± 7	45 ± 7	21.7 ± 6	15.3 ± 6	9.6 ± 5	73.9 ± 6
patients without relapse at BL	77	71.2 ± 7	42.3 ± 8	23.4 ± 7	9.3 ± 4	16.5 ± 8	71.2 ± 8
patients without relapse at 48^b	77	73 ± 6	46.2 ± 6	22.1 ± 6	14.8 ± 5	9.45 ± 4	74.5 ± 5
patients with relapse at BL	114	71.7 ± 8	43.5 ± 7	24.5 ± 6	9.3 ± 4	15.4 ± 7	70.7 ± 10
patients with relapse at 48^b	104	72.1 ± 8	45.9 ± 8	21.4 ± 6	15.8 ± 7	9.8 ± 5	73.6 ± 7.
patients without CDP at BL	154	71.3 ± 8	42.2 ± 8	24.5 ± 7	9.1 ± 4	17 ± 7	70.8 ± 9
patients without CDP at 48^b	148	72.5 ± 7	45.7 ± 8	22.2 ± 6	15.3 ± 6	9.9 ± 5	73.6 ± 6
patients with CDP at BL	37	73.4 ± 6	47 ± 7	23.1 ± 6	10 ± 4	13 ± 6	72.8 ± 6
patients with CDP at 48^b	33	74.6 ± 7	47.8 ± 7	20.5 ± 5	16.3 ± 6	8.4 ± 3	75.3 ± 6
b
	n	DR+ in T ly	CD45RA+	CD45RA+ in CD4+	CD5+ in B ly	CD5+ B ly
all patients at first relapse	191	10.8 ± 9	65.4 ± 11	58.8 ± 19	20 ± 16	2.1 ± 2
all patients at baseline (BL)^a	191	12.1 ± 11	65.2 ± 10	56.4 ± 20	18.1 ± 19	1.7 ± 2
all patients at 48 months (48)^b	181	12.2 ± 6	65.1 ± 8	44.8 ± 12	11.1 ± 7	1.7 ± 1
patients without relapse at BL	77	12.9 ± 11	64.9 ± 9	57.5 ± 20	23.3 ± 18	1.9 ± 3
patients without relapse at 48^b	77	12.1 ± 6	64.3 ± 8	45.2 ± 12	11.4 ± 8	1.9 ± 2
patients with relapse at BL	114	11.8 ± 10	63.4 ± 11	55.6 ± 21	18 ± 14	1.7 ± 2
patients with relapse at 48^b	104	12.8 ± 5	66.2 ± 8	44.8 ± 13	10 ± 6	1.7 ± 2
patients without CDP at BL	154	12.5 ± 10	64.8 ± 10	54.9 ± 20	18.1 ± 20	1.7 ± 2
patients without CDP at 48^b	148	12.4 ± 6	66.1 ± 8	45.8 ± 13	11.6 ± 8	1.9 ± 1
patients with CDP at BL	37	9.8 ± 9	62.4 ± 12	60.5 ± 23	16.7 ± 14	1.9 ± 2
patients with CDP at 48^b	33	11.1 ± 5	62.7 ± 9	40.7 ± 11	9.7 ± 5	1.4 ± 1

Double positive populations (HLA-DR + CD3+, CD45RA + CD4+, CD5 + CD19+) are expressed as the percentage of the first mentioned subpopulation in the basic population. CD5+ B lymphocytes are expressed as the originally measured value (percentage of total lymphocytes) to enable comparison with previously published results. [20]
^aThe laboratory test were done before intravenous steroids treatment, interval between this examination and baseline was 2–3 months
^bThe results at 48 months of following should be influenced by treatment (natalizumab n = 18, fingolimod n = 3, copaxone n = 6)
T ly – T lymphocytes (CD3+), B ly – B lymphocytes (CD19+), NK cells (CD3-CD16 + 56+)

Back to article page

ISSN: 1471-2377

Contact us

General enquiries: journalsubmissions@springernature.com